127 related articles for article (PubMed ID: 34763479)
1. Anorectal melanoma and gene analysis of personalized adjuvant therapy: a case report.
Cai X; Zhu X
Ann Palliat Med; 2021 Oct; 10(10):11216-11220. PubMed ID: 34763479
[TBL] [Abstract][Full Text] [Related]
2. Anorectal Mucosal Melanoma in the Era of Immune Checkpoint Inhibition: Should We Change Our Surgical Management Paradigm?
Adileh M; Yuval JB; Huang S; Shoushtari AN; Quezada-Diaz F; Pappou EP; Weiser MR; Garcia-Aguilar J; Smith JJ; Paty PB; Nash GM
Dis Colon Rectum; 2021 May; 64(5):555-562. PubMed ID: 33939387
[TBL] [Abstract][Full Text] [Related]
3. Anorectal melanoma.
Fastner S; Hieken TJ; McWilliams RR; Hyngstrom J
J Surg Oncol; 2023 Sep; 128(4):635-644. PubMed ID: 37395165
[TBL] [Abstract][Full Text] [Related]
4. Clinics, prognosis and new therapeutic options in patients with mucosal melanoma: A retrospective analysis of 75 patients.
Schaefer T; Satzger I; Gutzmer R
Medicine (Baltimore); 2017 Jan; 96(1):e5753. PubMed ID: 28072717
[TBL] [Abstract][Full Text] [Related]
5. Primary anorectal malignant melanoma: an uncommon anorectal pathology.
Juanmartiñena Fernández JF; Fernández-Urien I; Córdoba A
Rev Esp Enferm Dig; 2016 Sep; 108(9):604-5. PubMed ID: 27056438
[TBL] [Abstract][Full Text] [Related]
6. Anorectal Melanoma - a Histopathological Case Report and a Review of the Literature.
Kobakova I; Stoyanov G; Popov H; Spasova-Nyagulova S; Stefanova N; Stoev L; Yanulova N
Folia Med (Plovdiv); 2018 Dec; 60(4):641-646. PubMed ID: 31188769
[TBL] [Abstract][Full Text] [Related]
7. A Systematic Review of the Tumor-Infiltrating CD8
Shadbad MA; Asadzadeh Z; Hosseinkhani N; Derakhshani A; Alizadeh N; Brunetti O; Silvestris N; Baradaran B
Front Immunol; 2021; 12():734956. PubMed ID: 34603316
[TBL] [Abstract][Full Text] [Related]
8. Primary anorectal malignant melanoma: A clinical, radiology and pathology correlation.
Bohan S; Ramli Hamid MT; Poh KS; Chow TK; Chan WY
Malays J Pathol; 2020 Dec; 42(3):461-467. PubMed ID: 33361730
[TBL] [Abstract][Full Text] [Related]
9. Biological Factors behind Melanoma Response to Immune Checkpoint Inhibitors.
Olbryt M; Rajczykowski M; Widłak W
Int J Mol Sci; 2020 Jun; 21(11):. PubMed ID: 32517213
[TBL] [Abstract][Full Text] [Related]
10. Unexpected post-operative diagnosis of primary rectal melanoma. A case report.
Erdas E; Calò PG; Licheri S; Pomata M
G Chir; 2014; 35(5-6):137-9. PubMed ID: 24979106
[TBL] [Abstract][Full Text] [Related]
11. Anorectal malignant melanoma: treatment with surgery or radiation therapy, or both.
Moozar KL; Wong CS; Couture J
Can J Surg; 2003 Oct; 46(5):345-9. PubMed ID: 14577706
[TBL] [Abstract][Full Text] [Related]
12. Immune Profile Analysis in Peripheral Blood and Tumor in Patients with Malignant Melanoma.
Saito R; Sawada Y; Nakamura M
Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33669410
[TBL] [Abstract][Full Text] [Related]
13. Anorectal melanoma with a KIT-activating mutation, which is a target for tyrosine kinase inhibitor.
Itoh M; Goto A; Wakasugi H; Yoshida Y; Matsunaga Y; Fujii K; Suzuki K; Yonezawa K; Abe T; Arimura Y; Shinomura Y
Int J Clin Oncol; 2011 Aug; 16(4):428-34. PubMed ID: 21069551
[TBL] [Abstract][Full Text] [Related]
14. BRAF mutations distinguish anorectal from cutaneous melanoma at the molecular level.
Helmke BM; Mollenhauer J; Herold-Mende C; Benner A; Thome M; Gassler N; Wahl W; Lyer S; Poustka A; Otto HF; Deichmann M
Gastroenterology; 2004 Dec; 127(6):1815-20. PubMed ID: 15578519
[TBL] [Abstract][Full Text] [Related]
15. PD-L1 Expression and Immune Escape in Melanoma Resistance to MAPK Inhibitors.
Kakavand H; Rawson RV; Pupo GM; Yang JYH; Menzies AM; Carlino MS; Kefford RF; Howle JR; Saw RPM; Thompson JF; Wilmott JS; Long GV; Scolyer RA; Rizos H
Clin Cancer Res; 2017 Oct; 23(20):6054-6061. PubMed ID: 28724663
[No Abstract] [Full Text] [Related]
16. [Diagnosis and treatment of anorectal malignant melanoma--a report of 22 cases with literature review].
Zhong J; Zhou JN; Xu FP; Shang JQ
Ai Zheng; 2006 May; 25(5):619-24. PubMed ID: 16687086
[TBL] [Abstract][Full Text] [Related]
17. Dynamic Changes in PD-L1 Expression and Immune Infiltrates Early During Treatment Predict Response to PD-1 Blockade in Melanoma.
Vilain RE; Menzies AM; Wilmott JS; Kakavand H; Madore J; Guminski A; Liniker E; Kong BY; Cooper AJ; Howle JR; Saw RPM; Jakrot V; Lo S; Thompson JF; Carlino MS; Kefford RF; Long GV; Scolyer RA
Clin Cancer Res; 2017 Sep; 23(17):5024-5033. PubMed ID: 28512174
[No Abstract] [Full Text] [Related]
18. Predictive value of PD-L1 based on mRNA level in the treatment of stage IV melanoma with ipilimumab.
Brüggemann C; Kirchberger MC; Goldinger SM; Weide B; Konrad A; Erdmann M; Schadendorf D; Croner RS; Krähenbühl L; Kähler KC; Hafner C; Leisgang W; Kiesewetter F; Dummer R; Schuler G; Stürzl M; Heinzerling L
J Cancer Res Clin Oncol; 2017 Oct; 143(10):1977-1984. PubMed ID: 28616701
[TBL] [Abstract][Full Text] [Related]
19. [Primary anorectal melanoma].
Haddad F; Nadir S; Benkhaldoun L; Alaoui R; Cherkaoui A
Presse Med; 2005 Jan; 34(2 Pt 1):85-8. PubMed ID: 15687974
[TBL] [Abstract][Full Text] [Related]
20. JAK2, PD-L1, and PD-L2 (9p24.1) amplification in metastatic mucosal and cutaneous melanomas with durable response to immunotherapy.
Gupta S; Vanderbilt CM; Cotzia P; Arias Stella JA; Chang JC; Chen Y; Tang LH; DeLair DF; Yao J; Ladanyi M; Ross DS
Hum Pathol; 2019 Jun; 88():87-91. PubMed ID: 30236595
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
